(Q42671934)

English

Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome

scientific article published on 12 August 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

author name string

Peter K Sand

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Theodore M Johnson Ii

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Eric S Rovner

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Pamela I Ellsworth

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Michael G Oefelein

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

David R Staskin

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

publication date

12 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

107

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

612-620

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Tolterodine extended release is well tolerated in older subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Cumulative anticholinergic exposure is associated with poor memory and executive function in older men.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Frailty in older adults: evidence for a phenotype

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

New-onset incontinence and markers of frailty: data from the Hispanic Established Populations for Epidemiologic Studies of the Elderly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Urinary incontinence and its association with death, nursing home admission, and functional decline

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Effect of aging on the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Actigraphy-measured sleep characteristics and risk of falls in older women

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Trospium and cognition in patients with late onset Alzheimer disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.09519.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2010.09519.X

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42671934&oldid=1965050926"